Testosterone Treatment for Women: A Comprehensive Guide to Benefits, Dosing, and What to Expect

Why Testosterone in Women Has Been Misunderstood

Testosterone has been culturally and medically branded as the "male hormone" for decades. The science tells a different story.

Women's ovaries and adrenal glands produce testosterone throughout life. In premenopausal women, circulating testosterone levels are several times higher than estrogen levels in absolute terms—making testosterone the most abundant biologically active hormone in the female body. Testosterone in women contributes to libido and sexual function, but also to mood regulation, energy, motivation, cognitive function, bone density, muscle mass, body composition, joint comfort, and cardiovascular function.

Women's testosterone production declines progressively with age. The decline is gradual rather than abrupt: circulating levels drop approximately 50 percent between the mid-20s and menopause, with continued decline thereafter [1]. For women who undergo surgical menopause (bilateral oophorectomy) or experience adrenal insufficiency, the decline can be sudden and substantial.

The medical community's historical reluctance to prescribe testosterone for women has roots in several distinct issues, most of which are now being actively revisited:

A training gap, not a safety problem. Medical schools have provided minimal education on women's hormone therapy generally and on testosterone specifically. Most primary care clinicians, including many gynecologists, have not been trained to prescribe testosterone for women. Many simply don't know how. The result is not that testosterone is dangerous—it is that the clinicians women see often don't have the tools to offer it.

Conflation of doses. Concerns about testosterone in women have often referenced effects observed at supraphysiologic doses (doses far above the female physiological range) and incorrectly applied those concerns to physiologic dosing. The dose makes the difference between benefit and harm—a principle this article will return to repeatedly.

The pellet problem. Pellet therapy in women has produced most of the documented serious side effects (irreversible voice changes, clitoral enlargement, significant hirsutism), because pellets often deliver testosterone levels well above the female physiological range and cannot be adjusted quickly once implanted. The pellet experience has unfairly colored the broader perception of testosterone therapy in women.

The marketing problem. Updated medical guidance, when it does emerge, often takes years to reach the clinicians actually seeing women. Even now, with multiple international medical bodies formally endorsing testosterone for HSDD and a growing evidence base for broader benefits, most women experiencing relevant symptoms are not offered testosterone as part of their care.

The current state of testosterone therapy for women reflects all of these factors converging. The treatment landscape is changing, but not as fast as the underlying biology demands.

What Testosterone Does in Women

Testosterone receptors are present throughout the female body. The effects of testosterone in women are not limited to libido—they extend across every system where these receptors are expressed.

Sexual Function and Desire

The most established effect. Testosterone influences libido, sexual desire, arousal, orgasm, and overall sexual satisfaction. Multiple randomized controlled trials have demonstrated improvements in sexual desire, sexual events, and sexual satisfaction with testosterone therapy in postmenopausal women.

Mood, Energy, and Motivation

Testosterone receptors are present throughout the brain, particularly in regions involved in mood regulation, motivation, and reward. Women on appropriate testosterone therapy frequently report improvements in:

• Energy and reduced fatigue
• Motivation and drive
• Sense of well-being and overall mood
• Reduced symptoms of low mood

A 2017 trial in women with treatment-resistant depression showed that low-dose testosterone augmentation produced significant improvements in depressive symptoms when added to standard antidepressant therapy [2]. Subsequent clinical experience has reinforced this finding across populations beyond treatment-resistant depression.

Cognitive Function

Testosterone has documented effects on verbal memory, processing speed, and aspects of cognitive function. Women undergoing surgical menopause have shown improvements in verbal memory and well-being on testosterone therapy in published trials. Many women describe improvements in cognitive clarity and focus—what is sometimes called "brain fog"—on appropriately dosed testosterone.

Musculoskeletal Health

Testosterone contributes to muscle protein synthesis, bone density, and body composition in both sexes. In women, testosterone therapy is associated with:

• Maintenance and modest increase in lean body mass
• Improved or maintained bone mineral density
• Improvement in joint discomfort, particularly in perimenopausal and postmenopausal women
• Favorable shifts in body composition, including reduction in body fat percentage

Joint pain is a particularly under-recognized manifestation of declining hormones in women. Many women report joint discomfort that emerges in perimenopause and is dismissed as unrelated to hormones. Testosterone receptors in joint tissue mean that declining testosterone can contribute to this discomfort—and replacement can help relieve it.

Skin, Hair, and Cardiovascular Function

Testosterone influences skin quality, hair growth patterns, and cardiovascular tissue. The effects are dose-dependent: at physiologic doses, most women experience benefits or no change in skin and hair quality; at supraphysiologic doses, unwanted skin and hair effects become more common.

For a broader treatment of women's hormone health, see our Women's Hormone Health Program.

The Evidence Picture

Understanding the evidence for testosterone therapy in women requires understanding a critical distinction: the difference between "insufficient evidence to make a broad recommendation" and "evidence that something doesn't work."

The most-cited authoritative reference is the 2019 Global Consensus Position Statement on testosterone therapy for women, published by ten international medical societies [1]. The statement is unambiguous in two directions: it formally endorses testosterone therapy for HSDD in postmenopausal women based on robust randomized controlled trial evidence, and it acknowledges that evidence for other indications—mood, energy, cognition, bone, body composition—is more limited.

The key point: limited evidence is not negative evidence. The reasons broader applications haven't been formally endorsed are largely structural:

• Most randomized trials of testosterone in women have measured sexual function endpoints, not mood, energy, or cognitive endpoints
• The trials that have measured these broader endpoints have been smaller, shorter, and less methodologically rigorous than the sexual-function trials
• Long-term safety trials require pharmaceutical-industry sponsorship, which has been minimal for testosterone in women because there is no FDA-approved product

The clinical experience of physicians who actively prescribe testosterone for women, however, consistently reports improvements across all these domains. The disconnect between formal trial evidence and clinical observation is real, and it reflects the limits of the trial system more than it reflects the limits of testosterone's effects.

For individual women, the practical implication is this: testosterone therapy for HSDD is well-established and supported by international consensus. Testosterone therapy for the broader symptom picture is biologically coherent, clinically reported, and reasonable to pursue under physician supervision—even though the formal trial evidence is still being developed.

This is the same logic that supports many widely-used medical interventions where pharmaceutical-grade trial evidence has lagged clinical experience. Vaginal estrogen for genitourinary symptoms is a recent example: the American Urological Association released its first comprehensive guideline on Genitourinary Syndrome of Menopause in April 2025, formally recommending vaginal estrogen for symptoms that have been undertreated for decades despite clear clinical benefit [3]. The biology and the clinical evidence had been there for years; the formal guideline took time to catch up. A similar trajectory is now underway for testosterone in women.

Who Should Consider Testosterone Therapy

Based on current biological understanding and clinical evidence, testosterone therapy may be reasonable to discuss with a clinician for women who:

• Have hypoactive sexual desire disorder (HSDD) with documented personal distress, particularly after menopause (natural or surgical)
• Have undergone bilateral oophorectomy or experienced premature ovarian insufficiency
• Have adrenal insufficiency causing measurably low androgen levels
• Are in perimenopause or postmenopause and experiencing symptoms of low energy, low mood, reduced motivation, joint discomfort, sleep disturbance, body composition changes, or cognitive symptoms that may reflect declining androgens
• Have completed appropriate workup to exclude other causes of these symptoms

The last point is important. Many of the symptoms associated with low testosterone—fatigue, low libido, mood changes, weight gain, joint pain—can have other causes (thyroid dysfunction, depression, sleep disorders, perimenopausal estrogen fluctuation, vitamin deficiencies, autoimmune conditions). Appropriate testosterone candidacy includes ruling out these alternative explanations.

Testosterone therapy may not be appropriate for women who are:

• Pregnant or breastfeeding (absolute contraindication)
• Trying to conceive (testosterone can affect ovulation)
• Diagnosed with hormone-sensitive cancers (breast, endometrial) without specialist input
• Experiencing undiagnosed vaginal bleeding (workup needed first)
• Diagnosed with polycystic ovary syndrome (PCOS) with elevated baseline androgens (testosterone therapy is contraindicated, as PCOS often involves relative testosterone excess)
• Severely compromised in liver function
• Experiencing significant baseline acne or hirsutism that suggests androgen excess

Forms of Testosterone Therapy for Women

Several forms of testosterone are used clinically for women. The choice depends on patient preference, clinician experience, and the specific symptom picture.

Transdermal Cream (Most Recommended)

The most commonly prescribed and most-recommended form for women in the United States. Testosterone cream is compounded by 503A pharmacies and applied to skin (typically the inner thigh, lower abdomen, or forearm) once daily.

• Advantages: Predictable absorption, easy to dose, easily adjustable up or down, lowest risk of supraphysiologic peaks, easy to stop. Considered the safest delivery method by most clinicians who actively prescribe testosterone for women.
• Typical dose: 0.5 mL daily, with individual adjustment based on lab response. Doses are roughly one-tenth of those used in men.
• Limitations: Daily application required; small risk of transfer to partners or children through skin-to-skin contact (mitigated by rotating sites and washing hands after application).

Compounded Capsules or Troches

Oral or sublingual testosterone preparations are less common in the U.S. but used by some clinicians.

• Advantages: Convenient dosing; may be preferred by women who don't want daily skin application.
• Limitations: Oral testosterone has historically been associated with liver effects, leading most prescribers to favor transdermal delivery. Troches (sublingual) bypass first-pass metabolism but produce less predictable absorption than transdermal.

Pellets (Generally Not Recommended)

Small testosterone pellets implanted subcutaneously every 3–6 months. Used by some practitioners, but most experts in women's testosterone therapy now advise against them.

• Why pellets are problematic in women: Once implanted, the dose cannot be adjusted or stopped quickly if side effects develop. Pellets often deliver testosterone levels well above the female physiological range, particularly in the weeks immediately after implantation. Published case series have documented women receiving pellet doses producing testosterone levels several times the upper limit of the female reference range, with associated voice changes, clitoral enlargement, and significant hirsutism—some of which have been irreversible.
• Major endocrine and urologic societies do not recommend pellet therapy for women. Cedars-Sinai's clinical guidance describes pellet therapy in women as "uncommon and controversial" [4]. If a clinician offers pellets as the only option, that is a sign their toolbox is incomplete.

Injectable Testosterone

Intramuscular testosterone injections used at male doses are not appropriate for women. Some practitioners use very small doses of injectable testosterone weekly in women, but this is uncommon, harder to titrate than transdermal, and not standard practice.

Off-Label Use of Male-Approved Products

Some clinicians prescribe products FDA-approved for men (such as AndroGel) at lower doses for women off-label. This is legal and clinically reasonable when dosed appropriately—a small fraction of a male dose can produce female-physiologic blood levels—but requires careful titration. Compounded preparations are generally preferred because they allow more precise dosing for women.

Dosing and Monitoring

The fundamental principle of testosterone dosing in women is to keep circulating levels within the normal premenopausal female range. The reference range for total testosterone in adult women is approximately 15–70 ng/dL (depending on the lab and assay), with most clinicians targeting the upper end of this range for women with significant symptoms.

Typical starting dose:

• Transdermal cream: 0.5 mL daily, applied to skin
• Approximately one-tenth of male dosing

Monitoring schedule:

• Comprehensive baseline hormone panel before starting therapy, including total and free testosterone, estradiol, DHEA-S, progesterone, thyroid function, and other relevant markers
• Follow-up testosterone level at 4–6 weeks to verify therapeutic range
• Periodic re-testing every 6 months while on therapy
• Clinical re-evaluation for response and any side effects at each follow-up

Goal: Symptomatic improvement with circulating testosterone within the female physiological range. The therapeutic window is wide enough to produce meaningful effects without exceeding the safety range.

For most women, dosing adjustments are made based on the combination of lab values and clinical response. Lab values alone are not sufficient—some women feel best at the low end of the reference range, others at the high end. Tracking how the patient feels alongside the lab numbers is essential.

For a complete treatment of hormone testing, see our Complete Female Hormone Panel.

Side Effects: What to Expect

At physiologic doses—those keeping testosterone levels within the female reference range—side effects are uncommon. When they occur, they are typically dose-dependent and reversible by lowering the dose.

Possible side effects of testosterone therapy in women:

• Mild acne. The most common side effect. Often resolves with dose adjustment.
• Mild increase in facial or body hair. Most common in genetically predisposed women. Usually reversible with dose reduction.
• Hair changes on the scalp. Some women experience either improvement or thinning of scalp hair patterns.
• Voice changes (deepening). Rare at physiologic doses. Important to recognize early because voice changes can be irreversible if the dose is not promptly reduced.
• Mood changes. Most often positive (improved mood, more motivation), but occasionally irritability or increased aggression, particularly at higher doses.
• Clitoral enlargement. Rare at physiologic doses; more common with supraphysiologic exposure. Can be irreversible if not addressed.
• Mild skin or hair greasiness.
• Skin reaction at application site (for transdermal preparations).

Risk factors for side effects:

The single most important risk factor is dosing above the female physiological range. Most documented serious side effects in women have occurred with pellet therapy or self-administered male-dose products. With properly dosed transdermal therapy and regular monitoring, these events are rare.

This is the single most important safety principle in female testosterone therapy: the dose makes the difference between benefit and harm. Done correctly, side effects are uncommon and reversible. Done incorrectly—particularly through pellet therapy or unmonitored dosing—they can be significant and sometimes irreversible.

How Long Does It Take to Work?

Different effects emerge on different timelines:

• Mood, energy, and sleep: Many women notice changes within 2–4 weeks.
• Libido and sexual function: Full effects typically emerge over 6–12 weeks, with most women experiencing meaningful change by 3 months.
• Cognitive function and clarity: 4–12 weeks for most who respond.
• Joint comfort: 4–12 weeks for most.
• Body composition (lean mass, fat distribution): Months to a year of consistent therapy.
• Bone density: Measurable changes typically take 12 months or more.

Most clinicians recommend trying testosterone therapy for at least 3–4 months before evaluating overall response. Patients who show no improvement on any dimension after 6 months of appropriately dosed therapy may be considered non-responders.

Testosterone Plus Estrogen and Progesterone

Testosterone therapy in women is often—though not always—part of a broader hormone optimization approach that may also include estrogen and progesterone. For postmenopausal women, this is the typical pattern.

The hormones work in complementary ways:

• Estrogen primarily addresses hot flashes, vaginal symptoms, sleep, bone protection, and cardiovascular tissue
• Progesterone is essential for women with a uterus on estrogen and contributes to sleep, anxiety reduction, and mood
• Testosterone primarily addresses libido, mood, energy, motivation, lean tissue preservation, and joint comfort

Many women benefit from a coordinated regimen of all three. The integrated approach generally produces better symptom relief than addressing any single hormone in isolation.

The 2025 AUA Genitourinary Syndrome of Menopause guideline reinforces a related point: vaginal estrogen is a strong recommendation for women with vulvovaginal symptoms, recurrent urinary tract infections, dryness, or pain with intercourse—and is often prescribed alongside systemic hormone therapy for women experiencing multiple categories of symptoms [3]. For many women, comprehensive hormonal care involves multiple interventions targeting different symptom domains.

For a comprehensive treatment of integrated hormone replacement, see our Women's Hormone Health Program.

Testosterone and GLP-1 Therapy: The Body Composition Question

The conversation about testosterone in women has changed in one important practical respect over the past few years: a substantial and growing proportion of women in midlife are now on GLP-1 receptor agonists (semaglutide, tirzepatide, and others) for weight management. This creates a specific clinical question that the broader testosterone literature has not historically addressed but that matters enormously in practice.

The body composition problem. GLP-1 receptor agonists are remarkably effective at producing weight loss. What is less commonly discussed is the composition of that weight loss. Studies suggest that up to 25–40 percent of the weight lost during GLP-1 therapy may come from lean mass—primarily skeletal muscle—if active steps are not taken to preserve it.

For a menopausal woman, this matters substantially:

• Skeletal muscle is the primary site of insulin-mediated glucose disposal. Losing it worsens the insulin resistance that GLP-1 therapy is designed to improve.
• Muscle is metabolically active at rest. Losing it reduces basal energy expenditure, which can blunt long-term weight maintenance.
• Muscle is the biological substrate of physical strength, balance, and functional independence.
• Menopausal women are already on a sarcopenic trajectory before any GLP-1 therapy begins. The hormonal withdrawal of estrogen and testosterone has already started reducing lean tissue. GLP-1-driven weight loss accelerates an existing process.

Where testosterone fits. Testosterone is one of the most direct hormonal levers for muscle preservation in women. Its decline is a key driver of midlife sarcopenia, and its restoration—where clinically appropriate—provides a biologically coherent way to shift the composition of GLP-1-driven weight loss toward fat rather than lean tissue.

The framing is straightforward: GLP-1 therapy opens the door to significant fat reduction, but without attention to muscle preservation, some of what walks out that door is tissue the body cannot easily afford to lose. Testosterone helps keep that tissue in place while the fat reduction proceeds.

This is not a recommendation to add testosterone to every GLP-1 protocol. The decision still depends on individual indication, baseline hormone levels, symptoms, and contraindications. But for women in midlife who are already candidates for testosterone therapy and who are also on GLP-1s, the case for combining the two is particularly strong—and the consequences of leaving testosterone out are particularly meaningful.

For a deeper treatment of how hormone therapy and GLP-1 receptor agonists work together more broadly, see our analysis of HRT and GLP-1 combination therapy in menopause.

Common Misconceptions

Several beliefs about testosterone therapy in women persist despite being inconsistent with current evidence and clinical practice.

"Testosterone will make women bulky or masculine." Not at physiologic doses. The doses used in women are approximately one-tenth of male doses and are designed to keep circulating levels within the normal female range. Visible muscle gain or masculine features require supraphysiologic dosing, which is not the goal of properly conducted therapy.

"Testosterone is just for sex drive." Sexual desire is the indication with the strongest formal trial evidence, but testosterone receptors are present throughout the brain, bone, muscle, and other tissues. Effects on mood, energy, motivation, cognitive function, joint comfort, and body composition are biologically coherent and consistently reported clinically.

"Symptoms equal low testosterone." Many of the symptoms associated with low testosterone—fatigue, low libido, mood changes, weight gain, joint pain—can have other causes that need to be ruled out before attributing them to testosterone. Treating with testosterone without addressing alternative causes is not appropriate.

"Testosterone levels in women correlate directly with symptoms." Research has not consistently shown that lower testosterone levels predict more severe symptoms or that response to therapy correlates with starting level. Treatment decisions should be based on the combination of symptoms, individual biology, and clinical judgment—not testosterone level alone.

"Testosterone is dangerous for women." At physiologic doses with appropriate monitoring, testosterone therapy is generally well-tolerated. Most documented serious side effects in women have occurred at supraphysiologic doses, most often from pellet therapy. Properly conducted therapy has a favorable safety profile.

"There's not enough evidence to prescribe testosterone for women." This is the misconception that has done the most harm. The biological case for testosterone's effects in women is strong, the trial evidence for HSDD is well-established, and the clinical evidence for broader benefits is consistent across many practices and many women. The formal regulatory and consensus framework is catching up to what has been clinically evident for years, but the catch-up is well underway.

Frequently Asked Questions

What is testosterone therapy for women?

Testosterone therapy for women involves replacing or supplementing testosterone using small doses—typically about one-tenth of those used in men—to maintain circulating testosterone within the normal female physiological range. The most common form is a daily transdermal cream applied to skin. Evidence supports its use for HSDD, with clinical evidence supporting broader benefits for mood, energy, motivation, cognitive function, body composition, and joint comfort.

Is testosterone therapy safe for women?

At physiologic doses with appropriate monitoring, testosterone therapy is generally well-tolerated. Side effects are usually mild and reversible at proper doses. Safety risks increase substantially when doses exceed the female physiological range, which is why regular hormone testing and ongoing physician oversight are essential. Long-term safety beyond 1–2 years has not been formally established by long-duration randomized trials, though clinical experience and observational data have not surfaced major safety signals when therapy is properly conducted.

Is testosterone therapy approved by the FDA for women?

No. There is no FDA-approved testosterone formulation specifically for women in the United States. Treatment uses either small doses of products FDA-approved for men (prescribed off-label) or compounded preparations from 503A compounding pharmacies. This is one of the major regulatory gaps in U.S. women's health. Several other countries (United Kingdom, Australia, New Zealand, South Africa) have approved testosterone products specifically for women.

What are signs of low testosterone in women?

Common signs include reduced libido, fatigue, loss of motivation or drive, mood changes, joint discomfort, sleep disturbance, reduced lean muscle mass, increased body fat, cognitive fog, and reduced sense of well-being. None of these symptoms are specific to low testosterone—they can also reflect thyroid dysfunction, depression, sleep disorders, or perimenopausal hormonal changes. Diagnostic workup typically includes a comprehensive hormone panel rather than testosterone alone.

How is testosterone dosed for women?

Most commonly as a transdermal cream applied once daily, with doses individualized by lab response. A typical starting dose is 0.5 mL daily, with adjustments based on response. Doses are approximately one-tenth of those used in men. The goal is to keep blood testosterone within the normal female premenopausal range.

What are the side effects of testosterone therapy in women?

At physiologic doses, side effects are uncommon and typically mild. The most common are mild acne and slight increases in body hair, both usually reversible with dose adjustment. Voice changes and clitoral enlargement can occur at supraphysiologic doses and may be irreversible if not promptly addressed. The vast majority of documented serious side effects in women have been associated with pellet therapy or unmonitored dosing.

How long does it take testosterone to work in women?

Different effects emerge on different timelines. Mood, energy, and sleep changes often appear within 2–4 weeks; libido and sexual function effects typically take 6–12 weeks; cognitive and joint comfort effects emerge over 4–12 weeks; body composition changes take months to a year. Most clinicians recommend trying testosterone therapy for at least 3–4 months before evaluating response.

Will testosterone therapy make me look masculine or bulky?

No, not at physiologic doses. Doses used in women are designed to keep testosterone in the normal female range and are too low to produce visible muscle gain or masculine features. These changes require supraphysiologic dosing, which is not appropriate for women.

Can testosterone therapy help with menopause symptoms?

Yes, for many women. Testosterone therapy can address several common menopause-related symptoms: reduced libido, mood changes, fatigue, loss of motivation, joint discomfort, and changes in body composition. It does not specifically address hot flashes or vaginal symptoms, which are better managed with estrogen replacement. Testosterone is often used as part of a coordinated hormone replacement approach in menopause, alongside estrogen and (if uterus present) progesterone.

How is testosterone different in women vs. men?

Women produce testosterone in the ovaries and adrenal glands; men produce it primarily in the testes. Circulating testosterone levels are roughly 10 times lower in women than in men. Despite the lower absolute levels, testosterone is the most abundant biologically active hormone in the female body—higher than estrogen in absolute terms. The dosing for testosterone therapy reflects this physiological difference: doses for women are approximately one-tenth of those used in men.

Can testosterone therapy help with joint pain?

Joint discomfort is a commonly under-recognized symptom of declining hormones in women. Testosterone receptors are present in joint tissue, and many women report improvement in joint comfort on appropriately dosed testosterone therapy. This is one of the symptoms most frequently reported clinically that has historically been dismissed as unrelated to hormones.

Can testosterone therapy help with brain fog and cognitive function?

Many women report improvements in cognitive clarity, focus, and reduction in "brain fog" on testosterone therapy. Testosterone receptors are present throughout the brain, and verbal memory has improved in trials of women undergoing surgical menopause on testosterone. The cognitive benefits of testosterone therapy are biologically coherent and consistently reported clinically.

What about testosterone pellets for women?

Pellet therapy is generally not recommended for women. Pellets often produce testosterone levels well above the female physiological range, cannot be adjusted once implanted, and have been associated with most of the documented serious side effects in women (irreversible voice changes, clitoral enlargement, significant hirsutism). Most experts in women's testosterone therapy now recommend against pellets. Transdermal cream is the preferred delivery method.

Should I take testosterone if I'm on a GLP-1 like Ozempic or Mounjaro?

For midlife women on GLP-1 receptor agonists, testosterone takes on additional clinical relevance. Studies suggest that 25 to 40 percent of GLP-1-driven weight loss can come from lean muscle mass if not actively addressed. For women already on a sarcopenic trajectory from declining estrogen and testosterone, this can compound an existing process. Testosterone is one of the most direct hormonal interventions for preserving muscle during rapid weight loss. Whether to add testosterone in this context still depends on individual indication, baseline levels, symptoms, and contraindications, but the case is particularly compelling for women who are otherwise candidates for testosterone therapy.

Can I take testosterone therapy if I have a breast cancer history?

Testosterone therapy is generally not recommended for women with hormone-sensitive cancer history without specialist input. Some observational data has suggested potential protective effects of testosterone against breast cancer, but the evidence is mixed and not sufficient to override caution in this population. Decisions in this context require careful consultation with both the prescribing clinician and oncology team.

How is testosterone monitored?

Through periodic blood testing of testosterone (total and free), often alongside estradiol, DHEA-S, and other relevant hormones. Initial follow-up at 4–6 weeks after starting therapy verifies that the dose has produced therapeutic levels without exceeding the female physiological range. Follow-up testing every 6 months thereafter ensures levels remain in the safe range and informs dose adjustments.

Where can I get testosterone therapy as a woman?

Testosterone therapy for women is available through physicians familiar with off-label hormone therapy, including some gynecologists, urologists with women's health focus, endocrinologists, integrative medicine practitioners, and women's-health-focused telemedicine providers. The key consideration is finding a clinician who actively prescribes testosterone for women and has experience with appropriate dosing and monitoring. Healthspan offers testosterone therapy for women as part of our Women's Hormone Health Program.

Does insurance cover testosterone therapy for women?

Insurance coverage for off-label testosterone therapy in women is variable and often limited. Most insurance plans do not cover compounded testosterone preparations for women. Cash prices for compounded testosterone cream typically run $30–$80 per month, often comparable to or less than insurance copays for many prescription medications.

How Healthspan Approaches Testosterone Therapy for Women

The Healthspan Women's Hormone Health Program provides physician-supervised testosterone therapy as part of a comprehensive approach to women's hormonal health. Our program includes:

• Baseline assessment. Comprehensive Complete Female Hormone Panel covering testosterone (total and free), estradiol, progesterone, DHEA-S, thyroid function, and other relevant markers
• Clinical evaluation. Detailed assessment of symptoms, medical history, and treatment goals to determine if testosterone therapy is appropriate
• Personalized prescription. Testosterone is typically prescribed as a compounded transdermal cream at individualized dosing, generally starting at 0.5 mL daily
• Ongoing monitoring. Follow-up labs at 4–6 weeks and every 6 months thereafter to verify therapeutic levels and adjust dose as needed
• Coordinated care. For women using testosterone as part of broader hormone replacement therapy, our clinicians coordinate the full hormonal protocol (estrogen, progesterone, testosterone) rather than treating any single hormone in isolation
• Health coaching. Dedicated coach support to address sleep, nutrition, movement, and stress as contributors to hormonal health alongside medication

Membership pricing for the Women's Hormone Health Program starts at $99/month on a three-month plan or $129 for a single month. Medication is billed separately and only when prescribed.

We are one of several legitimate options for women considering testosterone therapy. The right path depends on existing care relationships, symptoms, and preferences.

Conclusion

Testosterone has been one of the most misunderstood hormones in women's health for decades. Long branded as the "male hormone" despite being the most abundant biologically active hormone in the female body, it has been undertreated, underprescribed, and underrepresented in women's healthcare conversations.

The medical landscape is changing. The 2025 American Urological Association guideline on Genitourinary Syndrome of Menopause—the first comprehensive guideline of its kind—represents one example of how formal medical guidance is catching up with what clinicians and patients have understood for years. Similar updates are likely to emerge for testosterone in women as the trial evidence continues to develop.

What testosterone therapy offers women is not a marketing pitch or a wellness intervention. It is a clinically meaningful treatment with a strong biological foundation, well-established evidence for some indications, and consistent clinical evidence for many others. For women whose symptoms reflect declining testosterone—and for women whose lives have been narrowed by symptoms their previous clinicians attributed to "just getting older"—appropriately dosed testosterone therapy can be a significant intervention.

The decision should be made with a clinician familiar with both the medication and women's physiology, with appropriate baseline testing, ongoing monitoring, and willingness to individualize the regimen. Properly conducted, it has a favorable safety profile and can produce meaningful improvements in libido, mood, energy, motivation, cognitive clarity, joint comfort, body composition, and overall sense of well-being.

For women experiencing symptoms that might be related to declining testosterone, the next step is comprehensive hormone testing and a conversation with a clinician who is actively prescribing in this space. The treatment is available, the evidence base is growing, and the cultural shift in how medicine treats women in midlife is well underway.

Related Research

• The Case for Combining HRT and GLP-1s: A New Framework for Menopausal Healthspan
• Women's Hormone Health Program
• Testosterone Topical Cream
• Complete Female Hormone Panel
• Top 10 Longevity & Anti-Aging Breakthroughs of 2025